Following the approval, Elahere became the first and only FRα-directed antibody drug conjugate (ADC) approved specifically for patients with FRα positive, platinum-resistant ovarian cancer in ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα) platinum-resistant ovarian ...

The new survival data comes as AbbVie is already seeing strong take-up of Elahere, which was the centrepiece of its $10.1 billion takeover of ImmunoGen in 2023. The drug was given accelerated ...